ABVC (ABVC BioPharma) 14-Day RSI : 43.93 (As of Dec. 14, 2024)

View and export this data going back to 2004. Start your Free Trial

What is ABVC BioPharma 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-12-14), ABVC BioPharma's 14-Day RSI is 43.93.

The industry rank for ABVC BioPharma's 14-Day RSI or its related term are showing as below:

ABVC's 14-Day RSI is ranked better than
53.71% of 1523 companies
in the Biotechnology industry
Industry Median: 44.97 vs ABVC: 43.93

Competitive Comparison of ABVC BioPharma's 14-Day RSI

For the Biotechnology subindustry, ABVC BioPharma's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ABVC BioPharma's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ABVC BioPharma's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where ABVC BioPharma's 14-Day RSI falls into.

ABVC BioPharma (NAS:ABVC) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI

100

–

[ 100

( 1 + Average Gain

Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ABVC BioPharma (NAS:ABVC) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.

ABVC BioPharma 14-Day RSI Related Terms

Thank you for viewing the detailed overview of ABVC BioPharma's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.

ABVC BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ABVC BioPharma Inc (NAS:ABVC) » Definitions » 14-Day RSI

Comparable Companies

Traded in Other Exchanges

N/A

Address

44370 Old Warm Springs Boulevard, Fremont, CA, USA, 94538

Website

https://www.abvcpharma.com

ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.

Executives

Shuling Jiang	director, 10 percent owner	44370 OLD WARM SPRINGS BLVD., FREMONT CA 94538
Shih-chen Tseng	director	5F., NO. 41-1, LN. 12, SINDONG ST., SONGSHAN DIST, TAIPEI CITY F5 105065
Yoshinobu Odaira	director	4823 DUNDAS STREET, THOMDALE, LONDON X0 N6P 1J1
Norimi Sakamoto	director	4823 DUNDAS STREET, THRONDALE, LONDON X0 N6P 1J1
Shin-yu Miao	director	NO. 25-12, AMLIN RD., XITUN DIST., TAICHUNG CITY F5 407676
Tsung Shann Jiang	director, officer: CSO and Director	1197 LA PLURISSIMA PL, FREMONT CA 94539
Eugene Jiang	director, officer: Chairman of the Board & CBO	1197 LA PLURISSIMA PL, FREMONT CA 94539
Chang-jen Jiang	director	1197 LA PLURISSIMA PL, FREMONT CA 94539
Yen-hsin Chou	director	13F. NO. 2, MEISHU E. 8TH ST.,, GUSHAN DIST., KAOHSIUNG CITY F5 804413
Chi-hsin Richard King	officer: Chief Scientific Officer	11907 GRANT PLACE, SAINT LOUIS MO 63131
Howard Doong	officer: Chief Executive Officer	44370 OLD WARM SPRINGS BLVD., FREMONT CA 94538
Chihliang An	officer: Chief Financial Officer	32458 JEAN DR, UNION CITY CA 94587
Tsang Ming Jiang	director	1197 LA PURISSIMA PL, FREMONT CA 94539
Shulamit Lazar	director, 10 percent owner, officer: President,Secretary,Treasurer	8605 SANTA MONICA BOULEVARD, SUITE 41336, LOS ANGELES CA 90069
Kevin Patrick Stolz	officer: CFO & Controller	2701 CAMBRIDGE COURT, SUITE 100, AUBURN HILLS MI 48326